« Capital Efficiency -- That's the Ticket for Biotechs | Main | Oh, Woe! Pharmerging Markets Won't Save Big Pharma Revenue »



TrackBack URL for this entry:

Listed below are links to weblogs that reference Will Biosimilars Drive Process Innovation?:


Feed You can follow this conversation by subscribing to the comment feed for this post.


Feel the 'Aha' comment of Tom is becoming much more reality. As Ron said, price becomes the key for commercial success of biosimilars. Also, the number of competitors have grown hence early bird gets the chunk of pie, possibly exclusivity. Moreover, for interchangeability you need very less differences between biosimilar and innovator to build the confidence of regulator. Hence the development path has to be as short and optimum as possible. With highly innovative and incisive development at early stage (before Ph1) and showing absolute similarity can get concessions from regulators (like FDA) for shorter development time, hence faster to market and can be a winning formula!


I think you're right that there will be a barbell pattern here. Either invest as little as possible in the process development and get to market first, or take the approach that Momenta Pharma MNTA is, invest heavily in characterization and process development in order to so precisely copy the reference drug that they can achieve interchangeable status

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada